Ipilimumab and its toxicities: a multidisciplinary approach - Wikidata - awgldk - TriplyDB

Ipilimumab and its toxicities: a multidisciplinary approach

Ipilimumab and its toxicities: a multidisciplinary approach

http://www.wikidata.org/entity/Q33777476

about

Toxicity management of immunotherapy for patients with metastatic melanoma Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience Toxicities of Immunotherapy for the Practitioner Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Aptamers: A New Technological Platform in Cancer Immunotherapy Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond Prospects of immune checkpoint modulators in the treatment of glioblastoma Extracutaneous melanomas: a primer for the radiologist.Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.Melanoma: more answers, more questions Current concepts in the diagnosis and management of cytokine release syndrome.Cancer immunotherapy in clinical practice -- the past, present, and future.Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands.Nivolumab in NSCLC: latest evidence and clinical potential PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma Immune modulation for cancer therapy.Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.Translational research in oncology--10 years of progress and future prospects.Clinical impact of checkpoint inhibitors as novel cancer therapies.Immune-based therapies for childhood cancer.Iatrogenic pathology of the intestines.Management of pulmonary toxicity associated with targeted anticancer therapies.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Immune checkpoint inhibitors: a new frontier in bladder cancer.Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Combination cancer immunotherapies tailored to the tumour microenvironment.

P2860

Q26738662-2026485C-CA69-4A56-A97A-24D903E3F285 Q26775383-2D5C57F5-3EE7-4EAE-88B3-7E241EEEA01A Q26795509-D0F2127B-3A28-431D-BD81-7C9AB7145734 Q26853171-FDA41711-58CC-490C-8D30-8F8D4B6FA225 Q26995499-D4EC65F8-11A1-4774-8CF0-221BD5E688B9 Q27008140-3CAFCAC1-9B52-45AA-9064-3926274F1E46 Q27021570-8D438F14-A26A-4330-99E7-072EA4BEE44C Q27022789-3C2014B3-0F13-4861-8453-8DE0B56979DC Q28068981-E814931E-E209-4623-9DC5-A353D110CE41 Q28077815-4C9F3675-AE3A-41CD-899E-87263E37A269 Q28081371-88809BFA-ECCF-4461-89F4-7E46C3D8B6D3 Q30397680-AF61B0A6-D251-4E11-9118-EFC1B2F1F1CD Q33591598-4BFDC913-2D23-4DF2-B613-5FE72F068EA0 Q33623877-2324B9C5-0764-4731-B49E-7F2481671D4C Q33777422-E24FD9D5-701D-457A-8848-6DB43699EC99 Q33886879-7F3C11B6-10F9-4AD1-98D1-35FC9C4C3DA6 Q34309399-B3111534-41F7-439A-BE7B-8B7D2113B77D Q34431415-A58E3EE2-692A-4F0A-8137-FF40CDA1540D Q34466452-FD19E578-87D4-47F6-8254-DAD727A3B573 Q34550012-A792E270-2D28-4F1B-A019-20058CB250EA Q34667977-2D9B4C78-736D-46A3-BC6E-54A15FF6584F Q34686944-E1D3BA61-78C0-48C4-BE00-FA42B974D1DC Q35064059-F4BC2777-8F99-438A-970B-0021EEDBEA4D Q36173638-92CDC9BB-AD94-498B-BB21-B0EA9B1E883F Q36871188-49376BD6-384B-43F2-A2DD-25A63D85ED92 Q37265479-06262B35-120E-4607-99B9-3722189D8F9F Q37308199-5948F0BF-24B6-49EC-9E6D-C7B134A36703 Q37670024-6F834F38-1DF6-4509-AF49-5D7666D69FAF Q38246950-AECD4345-A7A3-4617-86DB-0D39BDDBE4D5 Q38257126-2394D580-4FC3-422A-B135-CEBD921164BF Q38262593-0E47CBE9-E186-4679-A66B-50858ED5BD86 Q38263108-25C94096-0A80-4039-B1E5-32375AE9F381 Q38339456-97B54217-5643-482B-A029-021BC28558F8 Q38570532-24E99147-D9A5-4433-8A70-F715C4071FCC Q38595251-EBBB3882-92EA-4565-B1D4-036E953E821F Q38612706-E1F04985-F4C5-4A1B-968F-E1F1536401A1 Q38615337-8BC23076-236E-48F3-859A-B59BFD7047C5 Q38632728-21AF6EF3-4E77-4959-9D77-D57BB06E6813 Q38636711-1CCB3F43-2AE5-49A7-8DC0-B9CFC79C79C0 Q38645178-2A47D940-0425-470B-9C2D-0A9334C51037

P2860

Ipilimumab and its toxicities: a multidisciplinary approach

http://www.wikidata.org/entity/Q33777476

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Ipilimumab and its toxicities: a multidisciplinary approach

@ast

Ipilimumab and its toxicities: a multidisciplinary approach

@en

type

label

Ipilimumab and its toxicities: a multidisciplinary approach

@ast

Ipilimumab and its toxicities: a multidisciplinary approach

@en

prefLabel

Ipilimumab and its toxicities: a multidisciplinary approach

@ast

Ipilimumab and its toxicities: a multidisciplinary approach

@en

P1433

Q33777476-D7C5A4EE-51CD-4D1C-BF29-F42146AB77B0

P1476

Q33777476-AF5EA39B-2ADC-432F-B260-B4FD90A1EA57

P2093

Q33777476-054C4DBD-D5DE-4656-AC18-967A77FBB495

Q33777476-5BE41FBF-19E9-4415-A6F5-77D8DBDE6207

Q33777476-6594A70E-D1CC-486C-A5AF-706DB5B0A9E7

Q33777476-69CD8EFE-A12A-45D1-B917-715816578420

P2860

Q33777476-09CD9CFB-9A91-496B-9A60-028D3FCF6B43

Q33777476-15337975-E5D4-4589-A6CE-353466EAB5B7

Q33777476-1F83C720-FC68-48C8-81E9-15FD3895C02C

Q33777476-2B45E533-4A8C-4244-8514-4C3E763CE0DF

Q33777476-38CAB670-F6B6-4B10-B560-53EF7599D934

Q33777476-3A2089C2-4291-4123-83D1-2DEE41CF6613

Q33777476-3D2F5651-FC00-45A4-B993-FAAE44F850C2

Q33777476-40AD221E-AFD7-46DE-BE23-6923EA8DFAED

Q33777476-414A80A7-98E5-46E5-B014-7F2456B49FEF

Q33777476-420BC3EA-129D-49A5-BD59-BD0D6CF853B0

P304

Q33777476-70DEDDE2-7D76-46C6-A66E-674841DC01A3

P31

Q33777476-84A5D08D-A1F4-4889-934A-D74AA93AD65E

P356

Q33777476-5BBB903B-DA52-4E9A-9DFF-F7448C32F9C6

P433

Q33777476-77770139-95D0-425E-9F95-D7681F2D620D

P478

Q33777476-0B7DD85B-FA22-41F6-AB66-2078BED67E2F

P577

Q33777476-1F446B28-9AC7-4DBD-9597-F44557745991

P698

Q33777476-BF998BFD-D102-435B-AAEE-697527C72383

P921

Q33777476-0E1D70A6-6D95-4B39-90BB-7F1CB62CD15C

P932

Q33777476-F743A493-12CB-45D0-ACEC-061740F8272B

P356

THEONCOLOGIST.2012-0483

P1433

P1476

Ipilimumab and its toxicities: a multidisciplinary approach

@en

P2093

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Weber

http://www.w3.org/2001/XMLSchema#string

Leslie A Fecher

http://www.w3.org/2001/XMLSchema#string

Sanjiv S Agarwala

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Cancer statistics, 2012

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Final version of 2009 AJCC melanoma staging and classification

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

P304

733-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0483

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23774827

http://www.w3.org/2001/XMLSchema#string

P921

P932

4063401

http://www.w3.org/2001/XMLSchema#string